Skip to content
Peptidepedia

Semax Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

Semax dosing is best understood through the two approved Russian formulations, supplemented by community experience with research-grade material.

Approved Russian Formulations:

  • 0.1% Solution (standard): Each drop delivers approximately 50 mcg. Standard dosing is 2 to 3 drops per nostril, 2 to 3 times daily (200 to 900 mcg/day) for courses of 10 to 30 days. Indicated for cognitive disorders, memory enhancement, encephalopathy, and general neuroprotection.
  • 1% Solution (high-dose): Each drop delivers approximately 500 mcg. Used under medical supervision for acute ischemic stroke, optic nerve atrophy, and severe neurological conditions at total daily doses of 3,000 to 9,000 mcg for courses of 5 to 14 days.

Community Protocols (Research Chemical):

  • Starting dose: 100 to 200 mcg intranasally once daily for 3 to 4 days to assess tolerance
  • Standard dose: 200 to 600 mcg daily, divided into one or two administrations
  • Higher dose: 600 to 900 mcg daily for cognitive performance or acute neuroprotective goals
  • Nasal spray: A standard 30 mg/10 mL nasal spray delivers approximately 300 mcg per pump

Timing and Cycling:

Morning administration is strongly preferred. The peptide cycling guide has structured on/off protocols relevant to nootropic peptides like Semax. Semax enhances dopaminergic tone and alertness, and afternoon or evening dosing may disrupt sleep. If splitting into two daily doses, the second dose should be taken before 2:00 to 3:00 PM. Standard course duration is 10 to 30 days. At doses above 900 mcg/day, courses typically do not exceed 30 days. At moderate doses (600 mcg/day), some researchers extend to 60 days. A washout period of 2 to 4 weeks between courses is common practice.

Frequently Asked Questions

The most common intranasal protocol uses 200 to 600 mcg per day, divided into one or two doses. A standard 0.1% nasal spray delivers approximately 300 mcg per pump. Morning administration is preferred due to dopaminergic stimulation. Clinical use in Russia employs 10 to 30 day courses, with the 1% solution reserved for acute neurological conditions under medical supervision.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Dergunova LV, Filippenkov IB, Stavchansky VV, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes (Basel). 2020;11(6):681.
  2. Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. BMC Neurosci. 2014;15:63.
  3. Shadrina MI, Dolotov OV, Grivennikov IA, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35.
  4. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500.
  5. Kaplan AY, Kochetova AG, Nezavibathko VN, Rzhevskii DA, Roshchina IF, Ashmarin IP. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2007;68(2):306-310.
  6. Gusev EI, Skvortsova VI, Chukanova EI. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68.
  7. Gavrilova SA, Golubev AI, Lipina TV, et al. Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(5):15-19.
  8. Ioseliani TK, Kozaev GG, Poletaeva II, Elizarova IP. Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone. Vestn Oftalmol. 2001;117(4):5-8.
  9. Filippenkov IB, Remizova JA, Denisova AE, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2024;44(1):71.
  10. Myasoedov NF, Andreyeva LA, Grigorjeva ME, et al. Development of peptide biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716.
  11. Stavchansky VV, Dergunova LV, Filippenkov IB, et al. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. Int J Mol Sci. 2021;22(12):6179.
←Read the full Semax guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”